Bukwang Pharmaceutical Co., Ltd.
https://www.bukwang.co.kr/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bukwang Pharmaceutical Co., Ltd.
Hanmi's Merger Plan Could Spark Power Struggle In South Korea Pharma Sector
An unexpected merger between Korea's Hanmi Pharm Group and chemical group OCI may raise eyebrows in terms of likely synergies, but analysts are viewing the planned transaction positively in terms of future cash flow. However, resistance from some members of Hanmi's founder family may mean a possible leadership struggle at the pharma company.
Hanmi Announces Merger While Possible Power Struggle Surfaces
An unexpected merger between Korea's Hanmi Pharm Group and chemical group OCI may raise eyebrows in terms of likely synergies, but analysts are viewing the planned transaction positively in terms of future cash flow. However, resistance from some members of Hanmi's founder family may mean a possible leadership struggle at the pharma company.
Deal Watch: Vanda Buys US, Canadian Rights To J&J’s Ponvory
Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.
Korean COVID-19 Contenders Still Racing Toward Finish Line
Hyundai Bioscience’s niclosamide-based oral antiviral moves into Phase II, joining other Korean COVID-19 treatment candidates in the pivotal trial stages, while SK Bioscience’s Phase III recombinant protein vaccine gears up for global market entry.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
- Other Names / Subsidiaries
-
- Concit Pharma ApS
- Contera Pharma
- Dyna Therapeutics Co., Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice